SubsidieMeestersA novel bioinformatics SaaS platform to identify and classify the pathogenicity of single genomic variants and oligogenic variant combinations for the diagnosis and treatment of genetic diseases
eVai is a SaaS platform that enhances genetic variant interpretation, enabling accurate and rapid identification of pathogenic variants to improve diagnostic yields for genetic diseases.
Projectdetails
Introduction
Genetic diseases affect over 300 million individuals worldwide, resulting in 2.8 million new patients every year. The advent of Next Generation Sequencing (NGS) means it is now possible to analyze the whole patient's genome.
Challenges in Genetic Diagnosis
However, variant interpretation is the biggest hindrance to the widespread adoption of NGS technologies. Hence, clinicians are struggling to identify disease-causing variants, and the diagnostic yield of genetic disorders is only about 50% on average.
eVai Platform
eVai is a revolutionary SaaS platform that allows geneticists to identify multiple pathogenic genomic variants with unprecedented accuracy and speed.
Key Features
We bring to market:
- The first and only digenic and oligogenic variant interpretation.
- Best predictive causative variant accuracy.
- Reduced turnaround time.
- Consistency of variant interpretation.
- Discovery of unknown variants.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.682.537 |
| Totale projectbegroting | € 2.403.625 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 31-3-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ENGENOME SRLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancerQlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe. | EIC Accelerator | € 2.491.650 | 2024 | Details |
Next generation gene writing platform to cure genetic and oncological diseasesIntegra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases. | EIC Accelerator | € 2.496.375 | 2024 | Details |
Transforming Molecular Diagnostics through NanoTechnologyAltratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification. | EIC Accelerator | € 2.499.999 | 2024 | Details |
in silico bio-evolutio - novel AI paradigm for molecular biologyThis project aims to accelerate phage therapy by using an AI platform for in silico simulations to optimize phage selection, reducing experimental time and enhancing personalized treatment effectiveness. | EIC Accelerator | € 1.692.596 | 2023 | Details |
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer
Qlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe.
Next generation gene writing platform to cure genetic and oncological diseases
Integra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases.
Transforming Molecular Diagnostics through NanoTechnology
Altratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification.
in silico bio-evolutio - novel AI paradigm for molecular biology
This project aims to accelerate phage therapy by using an AI platform for in silico simulations to optimize phage selection, reducing experimental time and enhancing personalized treatment effectiveness.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Genotype Landscape een big data gedreven platform voor zeldzame genetische ziektesHet project richt zich op het ontwikkelen van een platform voor marktonderzoek dat bedrijven helpt bij het nauwkeurig inschatten van doelgroepen voor therapieën van zeldzame erfelijke ziektes. | Mkb-innovati... | € 20.000 | 2020 | Details |
GeneticYou – Personal GenomicsOmnigen B.V. en Health E-Solutions B.V. ontwikkelen een softwaretool die DNA-variaties analyseert en gezondheidsrisico's voorspelt, gekoppeld aan smart-devices voor persoonlijke gezondheidsmonitoring. | Mkb-innovati... | € 294.196 | 2015 | Details |
Targeting the dark side of the human genome—non-coding regulatory elements—to treat diseasesTargetNCREs aims to harness therapeutic potential of non-coding regulatory elements through innovative high-throughput screening, validating targets for commercial applications and market development. | ERC Proof of... | € 150.000 | 2024 | Details |
Gepersonaliseerde Diagnostiek voor Genetische ZiektesVUS Diagnostics ontwikkelt een CDx-platform met een functionele assay en database op basis van prime editing/CRISPR-technologie voor diagnostisch onderzoek. | Mkb-innovati... | € 20.000 | 2023 | Details |
Computational multiplexing to optimise next-generation sequencingDeveloping MultiSeq, a bioinformatics solution to streamline and reduce costs in NGS library preparation, aiming to democratize sequencing technology and enhance its application across industries. | ERC Proof of... | € 150.000 | 2023 | Details |
Genotype Landscape een big data gedreven platform voor zeldzame genetische ziektes
Het project richt zich op het ontwikkelen van een platform voor marktonderzoek dat bedrijven helpt bij het nauwkeurig inschatten van doelgroepen voor therapieën van zeldzame erfelijke ziektes.
GeneticYou – Personal Genomics
Omnigen B.V. en Health E-Solutions B.V. ontwikkelen een softwaretool die DNA-variaties analyseert en gezondheidsrisico's voorspelt, gekoppeld aan smart-devices voor persoonlijke gezondheidsmonitoring.
Targeting the dark side of the human genome—non-coding regulatory elements—to treat diseases
TargetNCREs aims to harness therapeutic potential of non-coding regulatory elements through innovative high-throughput screening, validating targets for commercial applications and market development.
Gepersonaliseerde Diagnostiek voor Genetische Ziektes
VUS Diagnostics ontwikkelt een CDx-platform met een functionele assay en database op basis van prime editing/CRISPR-technologie voor diagnostisch onderzoek.
Computational multiplexing to optimise next-generation sequencing
Developing MultiSeq, a bioinformatics solution to streamline and reduce costs in NGS library preparation, aiming to democratize sequencing technology and enhance its application across industries.